Tag: world

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Chandigarh University holds 8th CU Online Annual Convocation; 363 Students Degrees Awarded

Chandigarh University Sings MoU with Global Consulting Giant PwC to Offer Online MBA Program330 Postgraduate and 33 Undergraduate Degrees Conferred to Online and Distance...

Fox ESS Unveils Dynamic Energy Ecosystem Alongside Its First Rebrand Area at SNEC 2026

SHANGHAI, June 6, 2026 /PRNewswire/ -- Fox ESS, a global leader in renewable energy solutions, successfully concluded SNEC 2026 following the official launch of its...

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast, Bharuch district, GujaratEmployees and communities work together to conserve...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

PICS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PicS N.V. and Announces Opportunity for Investors with Substantial Losses...

SAN DIEGO, June 5, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of PicS N.V. (NASDAQ: PICS) Class A common...

JEF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Launches Investigation into Jefferies Financial Group, Inc. and Encourages Investors and Potential Witnesses to Contact Law...

We are investigating whether Jefferies Financial Group Inc. & certain of its top executives made materially false &/or misleading statements to investors.

Bishop’s University researcher co-edits new international volume on language and classroom equity

SHERBROOKE, QC, June 5, 2026 /CNW/ - Every classroom in Canada is already multilingual. A new Bloomsbury column co-edited by Dr. Sunny Man Chu Lau,...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsWorld

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Former Pentagon Advisor: “The $2 Stock Sitting on America’s Greatest Untapped Treasure”

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Tag: world

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Chandigarh University holds 8th CU Online Annual Convocation; 363 Students Degrees Awarded

Fox ESS Unveils Dynamic Energy Ecosystem Alongside Its First Rebrand Area at SNEC 2026

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

PICS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PicS N.V. and Announces Opportunity for Investors with Substantial Losses...

JEF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Launches Investigation into Jefferies Financial Group, Inc. and Encourages Investors and Potential Witnesses to Contact Law...

Bishop’s University researcher co-edits new international volume on language and classroom equity

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us